Abstract

Nowadays a donor can be found for virtually all patients in need of an allogeneic stem cell transplantation, and the decision whether to use a matched or mismatched unrelated donor, an unrelated donor for umbilical cord blood transplantation (UCBT), or a haploidentical donor depends not only on the availability of the donor but also on patient-, disease-, and center-related factors. This paper summarizes the recent criteria in the selection of cord blood unit, including the cell dose requirement and the HLA typing for the optimal donor choice. The main strategies to optimize the results of UCBT, the conditioning regimens, and the use of antithymocyte globulin and the other platforms of graft-versus-host disease prophylaxis are discussed. The paper describes the results of UCBT in children and adults with malignant and nonmalignant diseases and the comparative analysis with other donor type and stem cell sources. Emerging strategies, focusing on the different platforms of ex vivo expansion and the new applications using cord blood stem cell, are also examined.

References

References
1.
Passweg
JR
,
Baldomero
H
,
Basak
GW
, et al
;
European Society for Blood and Marrow Transplantation (EBMT)
.
The EBMT activity survey report 2017: a focus on allogeneic HCT for nonmalignant indications and on the use of non-HCT cell therapies [published online ahead of print 6 February 2019]
.
Bone Marrow Transplant
.
doi:10.1038/s41409-019-0465-9
.
2.
Smith
AR
,
Wagner
JE
.
Alternative haematopoietic stem cell sources for transplantation: place of umbilical cord blood
.
Br J Haematol
.
2009
;
147
(
2
):
246
-
261
.
3.
Rocha
V
,
Wagner
JE
Jr
,
Sobocinski
KA
, et al
;
Eurocord and International Bone Marrow Transplant Registry Working Committee on Alternative Donor and Stem Cell Sources
.
Graft-versus-host disease in children who have received a cord-blood or bone marrow transplant from an HLA-identical sibling
.
N Engl J Med
.
2000
;
342
(
25
):
1846
-
1854
.
4.
Gragert
L
,
Eapen
M
,
Williams
E
, et al
.
HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry
.
N Engl J Med
.
2014
;
371
(
4
):
339
-
348
.
5.
Wagner
JE
Jr
,
Eapen
M
,
Carter
S
, et al
;
Blood and Marrow Transplant Clinical Trials Network
.
One-unit versus two-unit cord-blood transplantation for hematologic cancers
.
N Engl J Med
.
2014
;
371
(
18
):
1685
-
1694
.
6.
Barker
JN
,
Scaradavou
A
,
Stevens
CE
.
Combined effect of total nucleated cell dose and HLA match on transplantation outcome in 1061 cord blood recipients with hematologic malignancies
.
Blood
.
2010
;
115
(
9
):
1843
-
1849
.
7.
Ruggeri
A
.
Alternative donors: cord blood for adults
.
Semin Hematol
.
2016
;
53
(
2
):
65
-
73
.
8.
Eapen
M
,
Klein
JP
,
Sanz
GF
, et al
;
Center for International Blood and Marrow Transplant Research
.
Effect of donor-recipient HLA matching at HLA A, B, C, and DRB1 on outcomes after umbilical-cord blood transplantation for leukaemia and myelodysplastic syndrome: a retrospective analysis
.
Lancet Oncol
.
2011
;
12
(
13
):
1214
-
1221
.
9.
Eapen
M
,
Klein
JP
,
Ruggeri
A
, et al
;
Center for International Blood and Marrow Transplant Research, Netcord, Eurocord, and the European Group for Blood and Marrow Transplantation
.
Impact of allele-level HLA matching on outcomes after myeloablative single unit umbilical cord blood transplantation for hematologic malignancy
.
Blood
.
2014
;
123
(
1
):
133
-
140
.
10.
Eapen
M
,
Wang
T
,
Veys
PA
, et al
.
Allele-level HLA matching for umbilical cord blood transplantation for non-malignant diseases in children: a retrospective analysis
.
Lancet Haematol
.
2017
;
4
(
7
):
e325
-
e333
.
11.
Barker
JN
,
Boughan
K
,
Dahi
PB
, et al
.
Racial disparities in access to HLA-matched unrelated donor transplants: a prospective 1312-patient analysis
.
Blood Adv
.
2019
;
3
(
7
):
939
-
944
.
12.
Ballen
KK
,
Verter
F
,
Kurtzberg
J
.
Umbilical cord blood donation: public or private?
Bone Marrow Transplant
.
2015
;
50
(
10
):
1271
-
1278
.
13.
Dehn
J
,
Spellman
S
,
Hurley
CK
, et al
.
Selection of unrelated donors and cord blood units for hematopoietic cell transplantation: guidelines from NMDP/CIBMTR [published online ahead of print 10 July 2019]
.
Blood
.
doi:10.1182/blood.2019001212
.
14.
Takanashi
M
,
Atsuta
Y
,
Fujiwara
K
, et al
.
The impact of anti-HLA antibodies on unrelated cord blood transplantations
.
Blood
.
2010
;
116
(
15
):
2839
-
2846
.
15.
Ruggeri
A
,
Rocha
V
,
Masson
E
, et al
.
Impact of donor-specific anti-HLA antibodies on graft failure and survival after reduced intensity conditioning-unrelated cord blood transplantation: a Eurocord, Société Francophone d’Histocompatibilité et d’Immunogénétique (SFHI) and Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC) analysis
.
Haematologica
.
2013
;
98
(
7
):
1154
-
1160
.
16.
Ciurea
SO
,
Cao
K
,
Fernandez-Vina
M
, et al
.
The European Society for Blood and Marrow Transplantation (EBMT) consensus guidelines for the detection and treatment of donor-specific anti-HLA antibodies (DSA) in haploidentical hematopoietic cell transplantation
.
Bone Marrow Transplant
.
2018
;
53
(
5
):
521
-
534
.
17.
Saito
AM
,
Cutler
C
,
Zahrieh
D
, et al
.
Costs of allogeneic hematopoietic cell transplantation with high-dose regimens
.
Biol Blood Marrow Transplant
.
2008
;
14
(
2
):
197
-
207
.
18.
Sanz
J
,
Boluda
JC
,
Martín
C
, et al
;
Grupo Español de Trasplante Hematopoyético y Terapia Celular (GETH)
.
Single-unit umbilical cord blood transplantation from unrelated donors in patients with hematological malignancy using busulfan, thiotepa, fludarabine and ATG as myeloablative conditioning regimen
.
Bone Marrow Transplant
.
2012
;
47
(
10
):
1287
-
1293
.
19.
Ruggeri
A
,
Labopin
M
,
Sanz
G
, et al
;
ALWP-EBMT study
.
Comparison of outcomes after unrelated cord blood and unmanipulated haploidentical stem cell transplantation in adults with acute leukemia
.
Leukemia
.
2015
;
29
(
9
):
1891
-
1900
.
20.
Brunstein
CG
,
Gutman
JA
,
Weisdorf
DJ
, et al
.
Allogeneic hematopoietic cell transplantation for hematologic malignancy: relative risks and benefits of double umbilical cord blood
.
Blood
.
2010
;
116
(
22
):
4693
-
4699
.
21.
Brunstein
CG
,
Barker
JN
,
Weisdorf
DJ
, et al
.
Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease
.
Blood
.
2007
;
110
(
8
):
3064
-
3070
.
22.
Cutler
C
,
Ballen
K
.
Reduced-intensity conditioning and umbilical cord blood transplantation in adults
.
Bone Marrow Transplant
.
2009
;
44
(
10
):
667
-
671
.
23.
Weisdorf
D
,
Eapen
M
,
Ruggeri
A
, et al
.
Alternative donor transplantation for older patients with acute myeloid leukemia in first complete remission: a Center for International Blood and Marrow Transplant Research-Eurocord analysis
.
Biol Blood Marrow Transplant
.
2014
;
20
(
6
):
816
-
822
.
24.
Pascal
L
,
Tucunduva
L
,
Ruggeri
A
, et al
;
Eurocord and the European Society for Blood and Marrow Transplantation
.
Impact of ATG-containing reduced-intensity conditioning after single- or double-unit allogeneic cord blood transplantation
.
Blood
.
2015
;
126
(
8
):
1027
-
1032
.
25.
Nagler
A
,
Ruggeri
A
.
Haploidentical stem cell transplantation (HaploSCT) for patients with acute leukemia—an update on behalf of the ALWP of the EBMT
.
Bone Marrow Transplant
.
2019
;
54
(
suppl 2
):
713
-
718
.
26.
Ruggeri
A
,
Labopin
M
,
Bacigalupo
A
, et al
.
Post-transplant cyclophosphamide for graft-versus-host disease prophylaxis in HLA matched sibling or matched unrelated donor transplant for patients with acute leukemia, on behalf of ALWP-EBMT
.
J Hematol Oncol
.
2018
;
11
:
40
.
27.
Bacigalupo
A
,
Sica
S
,
Laurenti
L
, et al
.
Unrelated cord blood transplantation and post-transplant cyclophosphamide
.
Haematologica
.
2019
;
104
(
2
):
e77
-
e78
.
28.
Brunstein
CG
,
Miller
JS
,
McKenna
DH
, et al
.
Umbilical cord blood-derived T regulatory cells to prevent GVHD: kinetics, toxicity profile, and clinical effect
.
Blood
.
2016
;
127
(
8
):
1044
-
1051
.
29.
Ustun
C
,
Giannotti
F
,
Zhang
MJ
, et al
.
Outcomes of UCB transplantation are comparable in FLT3+ AML: results of CIBMTR, EUROCORD and EBMT collaborative analysis
.
Leukemia
.
2017
;
31
(
6
):
1408
-
1414
.
30.
Tschan-Plessl
A
,
Halter
JP
,
Heim
D
,
Medinger
M
,
Passweg
JR
,
Gerull
S
.
Synergistic effect of sorafenib and cGvHD in patients with high-risk FLT3-ITD+AML allows long-term disease control after allogeneic transplantation
.
Ann Hematol
.
2015
;
94
(
11
):
1899
-
1905
.
31.
Michel
G
,
Galambrun
C
,
Sirvent
A
, et al
.
Single- vs double-unit cord blood transplantation for children and young adults with acute leukemia or myelodysplastic syndrome
.
Blood
.
2016
;
127
(
26
):
3450
-
3457
.
32.
Peffault de Latour
R
,
Chevret
S
,
Jubert
C
, et al
;
Francophone Society of Bone Marrow Transplantation and Cellular Therapy
.
Unrelated cord blood transplantation in patients with idiopathic refractory severe aplastic anemia: a nationwide phase 2 study
.
Blood
.
2018
;
132
(
7
):
750
-
754
.
33.
Bejanyan
N
,
Brunstein
CG
,
Cao
Q
, et al
.
Delayed immune reconstitution after allogeneic transplantation increases the risks of mortality and chronic GVHD
.
Blood Adv
.
2018
;
2
(
8
):
909
-
922
.
34.
Bart
T
.
Cost effectiveness of cord blood versus bone marrow and peripheral blood stem cells
.
Clinicoecon Outcomes Res
.
2010
;
2
:
141
-
147
.
35.
Mayani
H
,
Wagner
JE
,
Broxmeyer
HE
.
Cord blood research, banking, and transplantation: achievements, challenges, and perspectives [published online ahead of print 14 May 2019]
.
Bone Marrow Transplant
.
doi:10.1038/s41409-019-0546-9
.
36.
van den Broek
BTA
,
Page
K
,
Paviglianiti
A
, et al
.
Early and late outcomes after cord blood transplantation for pediatric patients with inherited leukodystrophies
.
Blood Adv
.
2018
;
2
(
1
):
49
-
60
.
37.
Gluckman
E
,
Broxmeyer
HA
,
Auerbach
AD
, et al
.
Hematopoietic reconstitution in a patient with Fanconi’s anemia by means of umbilical-cord blood from an HLA-identical sibling
.
N Engl J Med
.
1989
;
321
(
17
):
1174
-
1178
.
38.
MacMillan
ML
,
DeFor
TE
,
Young
JA
, et al
.
Alternative donor hematopoietic cell transplantation for Fanconi anemia
.
Blood
.
2015
;
125
(
24
):
3798
-
3804
.
39.
Boelens
JJ
,
Aldenhoven
M
,
Purtill
D
, et al
;
Centre for International Blood and Marrow Research
.
Outcomes of transplantation using various hematopoietic cell sources in children with Hurler syndrome after myeloablative conditioning
.
Blood
.
2013
;
121
(
19
):
3981
-
3987
.
40.
Fernandes
JF
,
Rocha
V
,
Labopin
M
, et al
;
Eurocord and Inborn Errors Working Party of European Group for Blood and Marrow Transplantation
.
Transplantation in patients with SCID: mismatched related stem cells or unrelated cord blood?
Blood
.
2012
;
119
(
12
):
2949
-
2955
.
41.
Ruggeri
A
,
Michel
G
,
Dalle
JH
, et al
.
Impact of pretransplant minimal residual disease after cord blood transplantation for childhood acute lymphoblastic leukemia in remission: an Eurocord, PDWP-EBMT analysis
.
Leukemia
.
2012
;
26
(
12
):
2455
-
2461
.
42.
Baron
F
,
Ruggeri
A
,
Nagler
A
.
Methods of ex vivo expansion of human cord blood cells: challenges, successes and clinical implications
.
Expert Rev Hematol
.
2016
;
9
(
3
):
297
-
314
.
43.
Delaney
C
,
Heimfeld
S
,
Brashem-Stein
C
,
Voorhies
H
,
Manger
RL
,
Bernstein
ID
.
Notch-mediated expansion of human cord blood progenitor cells capable of rapid myeloid reconstitution
.
Nat Med
.
2010
;
16
(
2
):
232
-
236
.
44.
de Lima
M
,
McNiece
I
,
Robinson
SN
, et al
.
Cord-blood engraftment with ex vivo mesenchymal-cell coculture
.
N Engl J Med
.
2012
;
367
(
24
):
2305
-
2315
.
45.
Horwitz
ME
,
Wease
S
,
Blackwell
B
, et al
.
Phase I/II study of stem-cell transplantation using a single cord blood unit expanded ex vivo with nicotinamide
.
J Clin Oncol
.
2019
;
37
(
5
):
367
-
374
.
46.
Laughlin
MJ
,
Eapen
M
,
Rubinstein
P
, et al
.
Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia
.
N Engl J Med
.
2004
;
351
(
22
):
2265
-
2275
.
47.
Rocha
V
,
Labopin
M
,
Sanz
G
, et al
;
Eurocord-Netcord Registry
.
Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia
.
N Engl J Med
.
2004
;
351
(
22
):
2276
-
2285
.
48.
Eapen
M
,
Rocha
V
,
Sanz
G
, et al
;
National Cord Blood Program of the New York Blood Center
.
Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis
.
Lancet Oncol
.
2010
;
11
(
7
):
653
-
660
.
49.
Milano
F
,
Gooley
T
,
Wood
B
, et al
.
Cord-blood transplantation in patients with minimal residual disease
.
N Engl J Med
.
2016
;
375
(
10
):
944
-
953
.
50.
Brunstein
CG
,
Fuchs
EJ
,
Carter
SL
, et al
;
Blood and Marrow Transplant Clinical Trials Network
.
Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts
.
Blood
.
2011
;
118
(
2
):
282
-
288
.
51.
Karlsson
S
.
Tipping clonal hematopoiesis into transformation
.
N Engl J Med
.
2018
;
379
(
3
):
295
-
296
.
52.
Ciurea
SO
,
Al Malki
MM
,
Kongtim
P
, et al
.
The European Society for Blood and Marrow Transplantation (EBMT) consensus recommendations for donor selection in haploidentical hematopoietic cell transplantation [published online ahead of print 4 March 2019]
.
Bone Marrow Transplant
.
doi:10.1038/s41409-019-0499-z
.
53.
Cutler
C
,
Multani
P
,
Robbins
D
, et al
.
Prostaglandin-modulated umbilical cord blood hematopoietic stem cell transplantation
.
Blood
.
2013
;
122
(
17
):
3074
-
3081
.
54.
Farag
SS
,
Srivastava
S
,
Messina-Graham
S
, et al
.
In vivo DPP-4 inhibition to enhance engraftment of single-unit cord blood transplants in adults with hematological malignancies
.
Stem Cells Dev.
2013
;
22
(
7
):
1007
-
1015
.
55.
Brunstein
CG
,
McKenna
DH
,
DeFor
TE
, et al
.
Complement fragment 3a priming of umbilical cord blood progenitors: safety profile
.
Biol Blood Marrow Transplant
.
2013
;
19
(
10
):
1474
-
1479
.
56.
Popat
U
,
Mehta
RS
,
Rezvani
K
, et al
.
Enforced fucosylation of cord blood hematopoietic cells accelerates neutrophil and platelet engraftment after transplantation
.
Blood
.
2015
;
125
(
19
):
2885
-
2892
.
57.
Wagner
JE
, Jr.
,
Brunstein
CG
,
Boitano
AE
, et al
.
Phase I/II trial of stemregenin-1 expanded umbilical cord blood hematopoietic stem cells supports testing as a stand-alone graft
.
Cell Stem Cell.
2016
;
18
(
1
):
144
-
155
.
58.
Frassoni
F
,
Gualandi
F
,
Podesta
M
, et al
.
Direct intrabone transplant of unrelated cord-blood cells in acute leukaemia: a phase I/II study
.
Lancet Oncol
.
2008
;
9
(
9
):
831
-
839
.
59.
Stiff
PJ
,
Montesinos
P
,
Peled
T
, et al
.
Cohort-controlled comparison of umbilical cord blood transplantation using carlecortemcel-L, a single progenitor-enriched cord blood, to double cord blood unit transplantation
.
Biol Blood Marrow Transplant
.
2018
;
24
(
7
):
1463
-
1470
.
60.
Atsuta
Y
,
Suzuki
R
,
Nagamura-Inoue
T
, et al
.
Disease-specific analyses of unrelated cord blood transplantation compared with unrelated bone marrow transplantation in adult patients with acute leukemia
.
Blood
.
2009
;
113
(
8
):
1631
-
1638
.
61.
Brunstein
CG
,
Eapen
M
,
Ahn
KW
, et al
.
Reduced-intensity conditioning transplantation in acute leukemia: the effect of source of unrelated donor stem cells on outcomes
.
Blood
.
2012
;
119
(
23
):
5591
-
5598
.
62.
Keating
AK
,
Langenhorst
J
,
Wagner
JE
, et al
.
The influence of stem cell source on transplant outcomes for pediatric patients with acute myeloid leukemia
.
Blood Adv
.
2019
;
3
(
7
):
1118
-
1128
.
You do not currently have access to this content.